Riboflavin for Glutamate Reduction in Alcohol Withdrawal
Status:
Not yet recruiting
Trial end date:
2022-10-25
Target enrollment:
Participant gender:
Summary
This RCT intends to investigate the use of oral Riboflavin (Vitamin B2) for reduction of
blood glutamate levels in the setting of acute alcohol withdrawal. Participants will be
patients admitted to an inpatient hospital unit diagnosed with acute alcohol withdrawal. In
addition to receiving care as usual, they will be randomized to receive either 100mg TID
riboflavin or an identically dosed placebo. The primary outcome measure will be blood
glutamate levels. Secondary outcomes will include measures of alcohol withdrawal and alcohol
craving. The investigators hypothesize that those in the riboflavin group will have lower
blood levels of glutamate, as well as decreased symptoms of alcohol withdrawal.
Phase:
Phase 2
Details
Lead Sponsor:
Andrew Hughes Oregon Health and Science University